Advertisement

Topics

Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

13:01 EDT 14 Mar 2018 | BioPortfolio Report Blog

Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 Pipeline Review, H1 2018


Summary


Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation.


Activated p53 binds DNA and activates expression of several genes including microRNA miR34a, WAF1/CIP1 encoding for p21 and hundreds of other downstream genes. p21 binds to the G1S/CDK CDK4/CDK6, CDK2, and CDK1 complexes molecules important for the G1/S transition in the cell cycle inhibiting their activity.


Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 pipeline Target constitutes close to 22 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 3 and 3 respectively.


Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications NonSmall Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Colon Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme GBM, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme GBM, SmallCell Lung Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Renal Failure ARF Acute Kidney Injury, Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Effects, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Hematological Tumor, Hepatic Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor PNET, Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma and Solid Tumor.


The latest report Cellular Tumor Antigen p53 Pipeline Review, H1 2018, outlays comprehensive information on the Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


It also reviews key players involved in Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53

The report reviews Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics and enlists all their major and minor projects

The report assesses Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Cellular Tumor Antigen p53 Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...